We therefore propose a model in which dTMP produced by TS-overexpressing cancer cells is not only metabolized to support the uncontrolled proliferation, but can also partially sustain de-differentiation and EMT via DPYD-based pyrimidines degradation (Fig. 8). The gene discussed is TYMS; the disease is cancer.